2015
DOI: 10.1016/j.det.2015.05.012
|View full text |Cite
|
Sign up to set email alerts
|

Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma

Abstract: Traditional chemotherapies, interleukins, phosphorylase inhibitors, and proteasome inhibitors are important therapies available to patients with cutaneous T-cell lymphoma (CTCL). Traditional chemotherapies, both in combination and as single agents, are commonly used in relapsed, refractory CTCLs that behave in an aggressive manner. Interleukins, phosphorylase inhibitors, and proteasome inhibitors are less commonly used but data support a role in patients with more refractory disease.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 136 publications
(121 reference statements)
0
1
0
Order By: Relevance
“…In highly-selected patients, allogeneic stem-cell transplantation may be considered, as this may be curative in some patients [22]. Systemic treatment for relapsed/refractory CTCL has historically relied on traditional chemotherapeutics, retinoids interferons, interleukins, phosphorylase inhibitors, histone deacetylase or proteasome inhibitors; however, responses are often short-lived [23]. Response rates of the clinically approved histone deacetylase inhibitors romidepsin and vorinostat are typically <35%.…”
Section: Introductionmentioning
confidence: 99%
“…In highly-selected patients, allogeneic stem-cell transplantation may be considered, as this may be curative in some patients [22]. Systemic treatment for relapsed/refractory CTCL has historically relied on traditional chemotherapeutics, retinoids interferons, interleukins, phosphorylase inhibitors, histone deacetylase or proteasome inhibitors; however, responses are often short-lived [23]. Response rates of the clinically approved histone deacetylase inhibitors romidepsin and vorinostat are typically <35%.…”
Section: Introductionmentioning
confidence: 99%